TARGETED INHIBITION OF LEUKEMIA INHIBITORY FACTOR (LIF)/LIFR AXIS FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER

Evestra, Inc., Schertz TX

Investigators